Cover Image
市場調查報告書

MedCore:冠狀動脈支架的日本市場

Japan Market Report for Coronary Stents 2018 - MedCore

出版商 iData Research Inc. 商品編碼 616038
出版日期 內容資訊 英文 671 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
MedCore:冠狀動脈支架的日本市場 Japan Market Report for Coronary Stents 2018 - MedCore
出版日期: 2017年10月01日 內容資訊: 英文 671 Pages
簡介

本報告提供日本的冠狀動脈支架的市場調查,市場定義,疾病概要,新產品的組合和最新的核准趨勢,回收狀況,臨床試驗狀況,各產品種類的市場規模的變化與預測,市場成長的各種影響因素分析,競爭分析等彙整資料。

目錄

圖表

摘要整理

日本的介入性心臟學市場概要

競爭分析

市場趨勢

市場發展

對象市場

對象治療、手術

修訂履歷

調查手法

疾病概要

  • 基礎結構
  • 診斷、治療
    • 一般診斷
    • 冠狀動脈疾病 (CAD)
    • 心肌梗塞 (MI)
    • 心絞痛
  • 患者人口統計

產品分析

  • 產品系列
    • 冠狀動脈支架市場
      • 新產品、最新的核准趨勢
  • 法律規章上的課題、回收
    • Boston Scientific
      • 冠狀動脈支架
      • PTCA球囊導管
      • 冠狀動脈介入導管&導管導引線
      • 冠狀動脈末梢栓塞保護設備
      • 冠狀動脈血管閉塞設備
    • Cook Medical
      • 冠狀動脈支架
      • 冠狀動脈介入導管&導管導引線
    • Cordis (Cardinal Health)
      • PTCA球囊導管/擴張導管
      • 冠狀動脈介入導管&導管導引線
    • Medtronic
      • 冠狀動脈支架
      • PTCA球囊擴張術&擴張導管
      • 冠狀動脈介入導管&導管導引線
    • Merit Medical Systems
      • 冠狀動脈介入導管&導管導引線
      • 冠狀動脈引進導鞘
    • Spectranetics
      • 冠狀動脈旋切術設備
    • St. Jude Medical (Abbott Laboratories)
      • 冠狀動脈血管閉塞設備
      • 冠狀動脈介入導管&導管導引線
    • Vascular Solutions (Teleflex)
      • 冠狀動脈介入導管&導管導引線
    • Volcano Therapeutics (Philips Volcano)
      • 冠狀動脈介入導管&導管導引線
      • IVUS導管
    • 其他
  • 臨床試驗
    • Abbott Laboratories
    • Asahi Intecc
    • B. Braun
    • Biosensors
    • Biotronik
    • Boston Scientific
    • Medtronic
    • St. Jude Medical (Abbott Laboratories)
    • Terumo Interventional Systems (TIS)
    • 其他

冠狀動脈支架市場

  • 簡介
  • 市場概要
  • 市場分析、預測
    • 冠狀動脈支架:整體市場
    • 傳統金屬支架
    • 藥物釋放型型支架
  • 成長推動因素、阻礙要素
  • 市場佔有率分析

用語

附錄:企業新聞稿

目錄
Product Code: iDATA_JPIC18_MC_CS

Percutaneous transluminal coronary angioplasty (PTCA) is the preferred method for the treatment of patients suffering from angina or myocardial infarction (MI). The procedure is generally considered to be more effective than drugs and less invasive than coronary artery bypass graft (CABG) surgery. Angioplasty procedures are performed to dilate a blocked lumen of an artery and restore blood circulation. These procedures involve inserting a PTCA catheter into the femoral, radial or brachial arteries and extending the catheter across the targeted lesion to position the stent.

General Report Contents:

  • Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
  • Market Drivers & Limiters for each chapter segment
  • Competitive Analysis for each chapter segment
  • Section on recent mergers & acquisitions

Angioplasty procedures are performed only after a problem has been detected by a diagnostic procedure, such as X-ray based angiography. In addition to stents, angioplasty procedures utilize a number of accessory products including introducer sheaths, PTCA balloon catheters, interventional catheters and guidewires, diagnostic catheters and guidewires, atherectomy devices, chronic total occlusion (CTO) devices, vascular closure devices (VCD), intravascular ultrasound (IVUS) catheters and optical coherence tomography (OCT) catheters.

As of 2017, there are three main types of stents used for coronary applications: bare-metal,

drug-eluting and bioabsorbable stents. Bare-metal stents (BMS) consist of a wire mesh that is designed to expand and keep the lumen from closing again. BMS were introduced in 1994 by Johnson & Johnson and within a few years, millions of these devices were being placed worldwide. Because minimally invasive procedures such as angioplasties are faster, easier to perform, safer and less expensive than CABG procedures, far more patients could be treated than prior to stent introduction. After a few years of use, it was found that bare-metal stents, while effective at dilating arteries, were associated with a substantial risk of restenosis, where the arterial wall would heal over the stent and occlude the artery again.

Restenosis requires an additional stenting or CABG procedure to be performed, dramatically increasing costs as well as the risk to the patient. To counter the risk of restenosis, drug-eluting stents (DES) were developed. These stents are coated with a polymer containing a drug that inhibits healing and reduces the rate of restenosis.

Table of Contents

TABLE OF CONTENTS I

LIST OF FIGURES XXII

LIST OF CHARTS XXXI

EXECUTIVE SUMMARY 1

JAPAN INTERVENTIONAL CARDIOLOGY MARKET OVERVIEW 1

COMPETITIVE ANALYSIS 4

MARKET TRENDS 7

MARKET DEVELOPMENTS 9

MARKETS INCLUDED 10

PROCEDURES INCLUDED 11

VERSION HISTORY 11

RESEARCH METHODOLOGY 12

    • Step 1: Project Initiation & Team Selection 12
    • Step 2: Prepare Data Systems and Perform Secondary Research 15
    • Step 3: Preparation for Interviews & Questionnaire Design 17
    • Step 4: Performing Primary Research 18
    • Step 5: Research Analysis: Establishing Baseline Estimates 20
    • Step 6: Market Forecasts and Analysis 21
    • Step 7: Identify Strategic Opportunities 23
    • Step 8: Final Review and Market Release 24
    • Step 9: Customer Feedback and Market Monitoring 25

DISEASE OVERVIEW 26

  • 2.1 BASIC ANATOMY 26
  • 2.2 DISEASE TREATMENTS AND DIAGNOSTICS 28
    • 2.2.1 General Diagnostics 28
    • 2.2.2 Coronary Artery Disease (CAD) 28
    • 2.2.3 Myocardial Infarction (MI) 29
    • 2.2.4 Angina Pectoris 30
  • 2.3 PATIENT DEMOGRAPHICS 31
    • 2.3.1 General Statistics 31

PRODUCT ASSESSMENT 33

  • 3.1 PRODUCT PORTFOLIOS 33
    • 3.1.1 Coronary Stent Market 33
      • 3.1.1.1 Emerging products and latest approvals 35
  • 3.2 REGULATORY ISSUES AND RECALLS 40
    • 3.2.1 Boston Scientific 40
      • 3.2.1.1 Coronary Stent 40
      • 3.2.1.2 PTCA Balloon Catheter 40
      • 3.2.1.3 Interventional Coronary Catheters and Guidewires 41
      • 3.2.1.4 Coronary Embolic Protection Device 42
    • 3.2.2 Cardinal Health 42
      • 3.2.2.1 Coronary Vascular Closure Device 42
    • 3.2.3 Cook Medical 43
      • 3.2.3.1 Coronary Stent 43
      • 3.2.3.2 Interventional Coronary Catheters and Guidewires 43
    • 3.2.4 Cordis (Cardinal Health) 44
      • 3.2.4.1 PTCA Balloon Catheter/Dilation Catheters 44
      • 3.2.4.2 Interventional Coronary Catheters and Guidewires 45
    • 3.2.5 Medtronic 46
      • 3.2.5.1 Coronary Stent 46
      • 3.2.5.2 PTCA Balloon and Dilation Catheters 46
      • 3.2.5.3 Interventional Coronary Catheters and Guidewires 47
    • 3.2.6 Merit Medical Systems 50
      • 3.2.6.1 Interventional Coronary Catheters and Guidewires 50
      • 3.2.6.2 Coronary Introducer Sheath 52
    • 3.2.7 Spectranetics 53
      • 3.2.7.1 Coronary Atherectomy Device 53
    • 3.2.8 St. Jude Medical (Abbott Laboratories) 54
      • 3.2.8.1 Coronary Vascular Closure Device 54
      • 3.2.8.2 Interventional Coronary Catheters and Guidewires 54
    • 3.2.9 Vascular Solutions (Teleflex) 55
      • 3.2.9.1 Interventional Coronary Catheters and Guidewires 55
    • 3.2.10 Volcano Therapeutics (Philips Volcano) 56
      • 3.2.10.1 Interventional Coronary Catheters and Guidewires 56
      • 3.2.10.2 Intravascular Ultrasound (IVUS) Catheter 56
    • 3.2.11 Other Companies 57
      • 3.2.11.1 Coronary Stent and other Vascular Stents 57
      • 3.2.11.2 PTCA balloon catheter 57
      • 3.2.11.3 Interventional Coronary Catheters and Guidewires 58
      • 3.2.11.4 Coronary Atherectomy Device 60
      • 3.2.11.5 Coronary Introducer Sheath 61
      • 3.2.11.6 Intravascular Ultrasound (IVUS) Catheter 61
  • 3.3 CLINICAL TRIALS 62
    • 3.3.1 Abbott Laboratories 62
      • 3.3.1.1 Coronary Stent 62
    • 3.3.2 Asahi Intecc 71
      • 3.3.2.1 Interventional Coronary Catheters and Guidewires 71
    • 3.3.3 B. Braun 72
      • 3.3.3.1 Coronary Stent 72
      • 3.3.3.2 PTCA balloon catheter 73
    • 3.3.4 Biosensors 77
      • 3.3.4.1 Coronary Stent 77
    • 3.3.5 Biotronik 79
      • 3.3.5.1 Coronary Stent 79
      • 3.3.5.2 PTCA balloon catheter 82
    • 3.3.6 Boston Scientific 83
      • 3.3.6.1 Coronary Stent 83
      • 3.3.6.3 PTCA balloon catheter 86
      • 3.3.6.4 Coronary Embolic Protection Device 86
    • 3.3.7 Medtronic 87
      • 3.3.7.1 Coronary Stent 87
      • 3.3.7.2 Interventional Coronary Catheters and Guidewires 90
      • 3.3.7.3 Coronary Embolic Protection Device 91
    • 3.3.8 St. Jude Medical (Abbott Laboratories) 92
      • 3.3.8.1 Interventional Coronary Catheters and Guidewires 92
      • 3.3.8.2 Intravascular Ultrasound (IVUS) Catheter 92
      • 3.3.8.3 Optical Coherence Tomography Catheter 93
      • 3.3.8.4 Fractional Flow Reverse (FFR) Catheter 93
    • 3.3.9 Terumo Interventional Systems (TIS) 94
      • 3.3.9.1 Interventional Coronary Catheters and Guidewires 94
      • 3.3.9.2 Coronary Embolic Protection Device 94
    • 3.3.10 Other Companies 95
      • 3.3.10.1 Coronary Stent 95
      • 3.3.10.2 PTCA balloon catheter 107
      • 3.3.10.3 Interventional Coronary Catheters and Guidewires 108
      • 3.3.10.4 Coronary Embolic Protection Device 111
      • 3.3.10.5 Coronary Chronic Total Occlusion Crosser CTO 112
      • 3.3.10.7 Fractional Flow Reserve (FFR) Guidewire 113
      • 3.3.10.8 Optical Coherence Tomography (OCT) Guidewire 113

CORONARY STENT MARKET 115

  • 4.1 INTRODUCTION 115
  • 4.2 MARKET OVERVIEW 118
  • 4.3 MARKET ANALYSIS AND FORECAST 122
    • 4.3.1 Total Coronary Stent Market 122
    • 4.3.2 Bare-Metal Stent Market 124
    • 4.3.3 Drug-Eluting Stent Market 126
  • 4.4 DRIVERS AND LIMITERS 129
    • 4.4.1 Market Drivers 129
    • 4.4.2 Market Limiters 129
  • 4.5 COMPETITIVE MARKET SHARE ANALYSIS 131

ABBREVIATIONS 135

APPENDIX: COMPANY PRESS RELEASES 137

LIST OF CHARTS

  • Chart 1 1: Interventional Cardiology Market by Segment, Japan, 2014 - 2024 3
  • Chart 1 2: Interventional Cardiology Market Overview, Japan, 2017 & 2024 3
  • Chart 4 1: Coronary Stent Market by Segment, Japan, 2014 - 2024 120
  • Chart 4 2: Coronary Stent Market Breakdown, Japan, 2017 121
  • Chart 4 3: Coronary Stent Market Breakdown, Japan, 2024 121
  • Chart 4 4: Total Coronary Stent Market, Japan, 2014 - 2024 123
  • Chart 4 5: Bare-Metal Stent Market, Japan, 2014 - 2024 125
  • Chart 4 6: Drug-Eluting Stent Market, Japan, 2014 - 2024 128
  • Chart 4 7: Leading Competitors, Coronary Stent Market, Japan, 2017 134

LIST OF FIGURES

  • Figure 1 1: Interventional Cardiology Market Share Ranking by Segment, Japan, 2017 (1 of 2) 4
  • Figure 1 2: Interventional Cardiology Market Share Ranking by Segment, Japan, 2017 (2 of 2) 5
  • Figure 1 3: Companies Researched in this Report, Japan, 2017 6
  • Figure 1 4: Factors Impacting the Interventional Cardiology Market by Segment, Japan (1 of 2) 7
  • Figure 1 5: Factors Impacting the Interventional Cardiology Market by Segment, Japan (2 of 2) 8
  • Figure 1 6: Recent Events in the Interventional Cardiology Market, Japan, 2014 - 2017 9
  • Figure 1 7: Interventional Cardiology Markets Covered, Japan, 2017 10
  • Figure 1 8: Interventional Cardiology Procedures Covered, Japan, 2017 11
  • Figure 1 9: Version History 11
  • Figure 3 1: Coronary Stent Products by Company (1 of 3) 37
  • Figure 3 2: Coronary Stent Products by Company (2 of 3) 38
  • Figure 3 3: Coronary Stent Products by Company (3 of 3) 39
  • Figure 3 4: Class 1 Device Recall Boston Scientific Fetch 2 Aspiration Catheter 40
  • Figure 3 5: Class 2 Device Recall Boston Scientific, Small Peripheral Cutting BalloonTM 40
  • Figure 3 6: Class 2 Device Recall Boston Scientific, FlextomeTM Cutting BalloonTM 40
  • Figure 3 7: Class 2 Device Recall Boston Scientific ACUITY Pro Coronary Sinus Guide Catheter 41
  • Figure 3 8: Class 1 Device Recall Boston Scientific Fetch 2 Aspiration Catheter 41
  • Figure 3 9: Class 2 Device Recall Boston Scientific, FlextomeTM Cutting BalloonTM 41
  • Figure 3 10: Class 1 Device Recall RotaWire Elite and sireClip Torquer, Guidewire and Guidewire Manipulation Device, Floppy 42
  • Figure 3 11: Class 2 Device Recall MynxGrip Vascular Closure Device 42
  • Figure 3 12: Class 2 Device Recall Zilver 518RX Vascular Stent 43
  • Figure 3 13: Class 2 Device Recall Zilver 518 Vascular Self Expanding Stent 43
  • Figure 3 14: Class 2 Device Recall White Lumax Guiding Coaxial Catheter 43
  • Figure 3 15: Class 2 Device Recall Cordis POWERFLEX PRO PTA Dilatation Catheter 44
  • Figure 3 16: Class 2 Device Recall EMPIRA ? NC RX PTCA Dilatation Catheter 44
  • Figure 3 17: Class 2 Device Recall Cordis EMPIRA RX PTCA Dilatation Catheter 44
  • Figure 3 18: Class 2 Device Recall Cordis ADROIT 6F Guiding Catheter 45
  • Figure 3 19: Class 2 Device Recall Resolute Integrity Zotarolimuseluting Coronary Stent 46
  • Figure 3 20: Class 2 Device Recall PowerCross .018 OTW PTA Dilation Catheter 46
  • Figure 3 21: Class 2 Device Recall Ev3, Inc. (Medtronic) 46
  • Figure 3 22: Class 2 Device Recall NC Sprinter; Rapid Exchange Balloon Dilatation Catheter 47
  • Figure 3 23: Class 2 Device Recall Medtronic Launcher Coronary Guide Catheter 47
  • Figure 3 24: Class 2 Device Recall Launcher Coronary Guiding Catheter 47
  • Figure 3 25: Class 1 Device Recall ZINGER Steerable Guidewire 47
  • Figure 3 26: Class 1 Device Recall Cougar Nitinol Workhorse Guidewire 48
  • Figure 3 27: Class 1 Device Recall COUGAR Steerable Guidewire 48
  • Figure 3 28: Class 1 Device Recall THUNDER Steerable Guidewire 48
  • Figure 3 29: Class 1 Device Recall ProVia CROSSING GUIDEWIRE 48
  • Figure 3 30: Class 1 Device Recall ATTAIN HYBRID Guide Wire 49
  • Figure 3 31: Class 2 Device Recall Medtronic Zuma Guide Catheter 49
  • Figure 3 32: Class 2 Device Recall Merit Maestro Microcatheter 50
  • Figure 3 33: Class 2 Device Recall Merit Laureate Hydrophilic Guide Wire 50
  • Figure 3 34: Class 2 Device Recall Maestro Microcatheter, Merit Medical System 50
  • Figure 3 35: Class 2 Device Recall Performa Cardiac Multipack Catheter 51
  • Figure 3 36: Class 2 Device Recall Hydrophylic guidewire 51
  • Figure 3 37: Class 2 Device Recall PreludeEASE 52
  • Figure 3 38: Class 2 Device Recall Prelude Pro Sheath Introducter 52
  • Figure 3 39: Class 2 Device Recall Turbo Elite Atherectomy Catheter 53
  • Figure 3 40: Class 2 Device Recall ELCA Coronary Atherectomy Catheter 53
  • Figure 3 41: Class 2 Device Recall Vascular closure device 54
  • Figure 3 42: Class 3 Device Recall FastCath" Transseptal Guiding Introducer 54
  • Figure 3 43: Class 1 Device Recall TwinPass Dual Access Catheter 55
  • Figure 3 44: Class 2 Device Recall Percutaneous Catheter 55
  • Figure 3 45: Class 2 Device Recall Prestige Plus Wire 56
  • Figure 3 46: Class 2 Device Recall Volcano s5, s5i, CORE and CORE Mobile systems 56
  • Figure 3 47: Class 2 Device Recall Intravascular Ultrasound System 56
  • Figure 3 48: Class 2 Device Recall FLAIR Endovascular Stent Graft, Bard Peripheral Vascular 57
  • Figure 3 49: Class 1 Device Recall LifeStent Solo Vascular Stent, Bard Peripheral Vascular 57
  • Figure 3 50: Class 2 Device Recall PTA Balloon Dilatation Catheters 57
  • Figure 3 51: Class 2 Device Recall VIA 27 Microcatheters, Sequent Medical Inc. 58
  • Figure 3 52: Class 2 Device Recall Coronary Artery Perfusion Cannula with Balloon, Sorin Group USA, Inc. 58
  • Figure 3 53: Class 2 Device Recall Aortic Arch Cannula, Sorin Group USA, Inc. 58
  • Figure 3 54: Class 2 Device Recall Mallinckrodt Launcher Guiding Catheter, Stryker Sustainability Solutions 58
  • Figure 3 55: Class 2 Device Recall Distal Access Catheter (DAC), Concentric Medical Inc 59
  • Figure 3 56: Class 2 Device Recall Distal Access Catheter 59
  • Figure 3 57: Class 2 Device Recall Proplege Coronary Sinus Catheter, Edwards Lifesciences, LLC 59
  • Figure 3 58: Class 2 Device Recall Turbo Elite, ELCA Atherectomy Catheter, Spectranetics Corporation 60
  • Figure 3 59: Class 1 Device Recall Diamondback 360 Coronary Orbital Artherctomy System, Cardiovascular Systems, Inc. 60
  • Figure 3 60: Class 3 Device Recall Diamondback 360 Coronary Orbital Atherectomy System 60
  • Figure 3 61: Class 2 Device Recall VIA 27 Microcatheters, Sequent Medical Inc 61
  • Figure 3 62: Class 1 Device Recall Halo One ThinWalled Guiding Sheath, Bard Peripheral Vascular 61
  • Figure 3 63: Class 2 Device Recall SOUNDSTAR eco Catheter, Biosense Webster, Inc. 61
  • Figure 3 64: XIENCE Xpedition/Alpine in Routine Clinical Practice (IRIS XPEDITION) 62
  • Figure 3 65: Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC) 62
  • Figure 3 66: Trial of MiStent Compared to Xience in Japan (DESSOLVEJ) 63
  • Figure 3 67: Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis (HOST-ALPINE) 63
  • Figure 3 68: XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS) 64
  • Figure 3 69: Absorb IV Randomized Controlled Trial 64
  • Figure 3 70: Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA) 65
  • Figure 3 71: Xience Versus Synergy in Left Main PCI (IDEAL-LM) 65
  • Figure 3 72: Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent (TALENT) 66
  • Figure 3 73: XIENCE PRIME SV Everolimus Eluting Coronary Stent Post Marketing Surveillance (XIENCE PRIME SV PMS) 66
  • Figure 3 74: XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study (XP China SAS) 67
  • Figure 3 75: A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT) (ABSORB CHINA) 67
  • Figure 3 76: AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population (ABSORB JAPAN) 68
  • Figure 3 77: XIENCE PRIME Japan Post-Marketing Surveillance (PMS) 68
  • Figure 3 78: EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent, Performance, and Technique in Chronic Total Occlusions 69
  • Figure 3 79: Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE (PATRIOT) 69
  • Figure 3 80: Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction (APPOSITION V) 70
  • Figure 3 81: Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis (RESTORE) 70
  • Figure 3 82: The Asahi Intecc PTCA Chronic Total Occlusion Study (CTO-PCI) 71
  • Figure 3 83: Optilene® Suture for Coronary Artery Bypass Graft Surgery (OPTICABG) 72
  • Figure 3 84: Treatment of Coronary Artery Disease (CAD) With Bare Metal Stent (BMS) Followed by Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Eluting Stent 72
  • Figure 3 85: Paclitaxel Eluting Balloon Versus Drug Eluting Stent in Native Coronary Artery Stenoses of Diabetic Patients (PEPCAD IV) 73
  • Figure 3 86: Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR) 73
  • Figure 3 87: Paclitaxel-Eluting Balloon Angioplasty and Coroflex™-Stents in the Treatment of Bifurcated Coronary Lesions (PEPCAD V) 74
  • Figure 3 88: The Paclitaxel-Eluting Percutaneous Coronary Angioplasty (PTCA)-Balloon Catheter for the Treatment of Coronary Bifurcations (PEPCAD-BIF) 74
  • Figure 3 89: INDICOR The Paclitaxel-Eluting PTCA-Balloon Catheter in Combination With a Cobalt-Chromium Stent (INDICOR) 75
  • Figure 3 90: A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent (PEPCAD) 75
  • Figure 3 91: The Paclitaxel-Eluting Percutaneous Transluminal Coronary Angioplasty (PTCA) - Balloon Catheter in Coronary Artery Disease to Treat Chronic Total Occlusions (PEPCAD-CTO) 76
  • Figure 3 92: PEPCAD I. The Paclitaxel-Eluting PTCA-Balloon Catheter to Treat Small Vessel 76
  • Figure 3 93: LEADERS FREE II: BioFreedom™ Pivotal Study 77
  • Figure 3 94: BioFreedom US IDE Feasibility Trial 77
  • Figure 3 95: A Randomized Clinical Evaluation of the BioFreedom™ Stent (Leaders Free) 78
  • Figure 3 96: Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease (ABSORB-LONG) 79
  • Figure 3 97: BIOTRONIK Orsiro Pre-Marketing Registration (BIOFLOW-VI) 79
  • Figure 3 98: Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions 80
  • Figure 3 99: BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite 80
  • Figure 3 100: BIOHELIX-I Bare Metal Stent Study (BIOHELIX-I) 81
  • Figure 3 101: BIOFLOW III Asia Registry 81
  • Figure 3 102: BIOFLOW-III Israel Satellite Registry 81
  • Figure 3 103: Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT (REMEDEE-OCT) 82
  • Figure 3 104: Drug Eluting Pantera Lux Catheter Registry 82
  • Figure 3 105: Post-Approval Study of PROMUS Element™ in China (PEChina) 83
  • Figure 3 106: EVOLVE China Clinical Trial (EVOLVE China) 83
  • Figure 3 107: EVOLVE Short DAPT Study 84
  • Figure 3 108: PROMUS Element Plus US Post-Approval Study 84
  • Figure 3 109: The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s) 85
  • Figure 3 110: SYNERGY China: Assess SYNERGY Stent in China 85
  • Figure 3 111: Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter 86
  • Figure 3 112: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation 86
  • Figure 3 113: Safety and Efficacy of the CRE8 Stent for the Treatment of De Novo Coronary Artery Lesions 87
  • Figure 3 114: RESOLUTE ONYX Post-Approval Study (ONYX PAS) 87
  • Figure 3 115: Medtronic RevElution Trial (RevElution) 88
  • Figure 3 116: The European Bifurcation Club Left Main Study (EBC MAIN) 88
  • Figure 3 117: Medtronic Resolute Onyx 2.0 mm Clinical Study 88
  • Figure 3 118: Medtronic Resolute Onyx Core (2.25 mm - 4.0 mm) Clinical Study 89
  • Figure 3 119: Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY) 89
  • Figure 3 120: An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System (RI-US) 90
  • Figure 3 121: Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study (JUDGE) 90
  • Figure 3 122: Atrial Fibrillation Detected by Continuous ECG Monitoring (LOOP) 91
  • Figure 3 123: Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia (STAR-VT) 92
  • Figure 3 124: ILUMIEN III: OPTIMIZE PCI 92
  • Figure 3 125: ILUMIEN III: OPTIMIZE PCI 93
  • Figure 3 126: Portuguese Study on The Evaluation of FFR Guided Treatment of Coronary Disease (POST-IT) 93
  • Figure 3 127: Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study (JUDGE) 94
  • Figure 3 128: Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis 94
  • Figure 3 129: Firehawk™ Coronary Stent System in the Treatment of Total Coronary Artery Occlusion Lesion(s) 95
  • Figure 3 130: Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III) 95
  • Figure 3 131: Trial of MiStent Compared to Xience in Japan (DESSOLVEJ) 96
  • Figure 3 132: MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (JNIR) 96
  • Figure 3 133: Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation 97
  • Figure 3 134: BIONICS - Pharmacokinetics (PK) Trial (BIONICS) 97
  • Figure 3 135: Safety and Efficacy Study of the Amaranth Medical APTITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT II) 97
  • Figure 3 136: Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 ) 98
  • Figure 3 137: Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease (Firehawk_38) 98
  • Figure 3 138: Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (MEND II) 99
  • Figure 3 139: Safety and Efficacy Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT) 99
  • Figure 3 140: Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold (FANTOM II), Reva Medical 99
  • Figure 3 141: Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I) (FANTOM I), Reva Medical 100
  • Figure 3 142: NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial 100
  • Figure 3 143: A Prospective, Single-arm, Multi-centre, Observational, Real World Registry (Morpheus) 101
  • Figure 3 144: Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System (DIRECT II) 101
  • Figure 3 145: First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis 102
  • Figure 3 146: eTryton Left Main Registry Tryton Side Branch Stent® Tmt of Denovo CAD in LM and CFX Arteries (eTRYTONLM) 102
  • Figure 3 147: An Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study The BioMime™1 Trial (MeriT-II) 103
  • Figure 3 148: An BioMime Vs. Xience Randomised Control Clinical Study (meriT-V) 103
  • Figure 3 149: BIONICS Israel Trial 104
  • Figure 3 150: Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System 104
  • Figure 3 151: Sapphire II PRO US Clinical Study 105
  • Figure 3 152: Axetis Inert Coronary Stent System First In Man Clinical Investigation (AXETIS FIM) 105
  • Figure 3 153: Shockwave Coronary Rx Lithoplasty® Study (Disrupt CAD I) 105
  • Figure 3 154: Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation 106
  • Figure 3 155: Procedural Advantages of a Novel Drug-Eluting Coronary Stent 106
  • Figure 3 156: Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study 107
  • Figure 3 157: Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2) 107
  • Figure 3 158: Drug Eluting Balloon for Prevention of Constrictive Remodeling 108
  • Figure 3 159: Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent Restenosis 108
  • Figure 3 160: Real-time MRI Right Heart Catheterization Using Passive Catheters 109
  • Figure 3 161: A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions 109
  • Figure 3 162: Safety and Feasibility of Using a Single Transradial Guiding Catheter for Primary PCI (RAPID) 110
  • Figure 3 163: A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter 110
  • Figure 3 164: Performance of the CARDIOGARD Cannula (GECG) 111
  • Figure 3 165: DEFLECT II: A Study to Evaluate the Safety and Performance of the TriGuard™HDH in Patients Undergoing TAVR 111
  • Figure 3 166: Use of the GARDEX™ Embolic Protection Device During Percutaneous Coronary Interventions of Saphenous Vein Graft 112
  • Figure 3 167: Coherex WAVECREST I Left Atrial Appendage Occlusion Study 112
  • Figure 3 168: Trial to Compare FFR Measurement With a Non-Side-Hole Guide Catheter Vs. a Side-Hole Guide Catheter 113
  • Figure 3 169: Prospective Randomized Optical Coherence Tomography Oslo tRial (PROCTOR) 113
  • Figure 3 170: Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Stent Implantation (OCTACS) 114
  • Figure 4 1: Coronary Stent Market by Segment, Japan, 2014 - 2024 (JP¥M) 118
  • Figure 4 2: Coronary Stent Market by Segment, Japan, 2014 - 2024 (US$M) 119
  • Figure 4 3: Total Coronary Stent Market, Japan, 2014 - 2024 122
  • Figure 4 4: Bare-Metal Stent Market, Japan, 2014 - 2024 124
  • Figure 4 5: Drug-Eluting Stent Market, Japan, 2014 - 2024 127
  • Figure 4 6: Drivers and Limiters, Coronary Stent Market, Japan, 2017 130
  • Figure 4 7: Leading Competitors, Coronary Stent Market, Japan, 2017 133
  • Figure 6 1: Press Release Summary 137
Back to Top